iShares U.S. Pharmaceuticals ETF IHE
Set alert
At close · Oct 30
After hours · Oct 30, 5:43 PM ET
- YTD
- +26.85%
- 1 year
- +42.98%
- Open
- 108.43
- Prev close
- 106.61
- Mkt cap
- 1.21B
- Vol
- 395.46K
- Avg vol
- 225.76K
- EPS
- 3.82
- P/E
- 28.18
- Div yield
- 0.00%
More statistics
- Low
- 107.29
- High
- 109.43
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 102.38
- 200-d avg
- 94.66
5D chart
Signals (124)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 6 days ago |
| RSI: Oversold | Oct 26, 10:45 AM | 6 days ago |
News
3 days ago benzinga.com
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
5 days ago defenseworld.net
Capital Investment Advisors LLC Makes New $630,000 Investment in iShares U.S. Pharmaceuticals ETF $IHE
Capital Investment Advisors LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) in the third quarter, according to the company in its most recent filing with the…
6 days ago fool.com
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
2 weeks ago etftrends.com
From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's…
2 weeks ago fool.com
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
3 weeks ago fool.com
Better Pharma ETF: iShares IHE vs. State Street XPH
The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S.…
3 weeks ago zacks.com
Execution of Pharma Tariffs Brings These ETFs Into Focus
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
1 month ago zacks.com
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the…
1 month ago seekingalpha.com
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity…
1 month ago seekingalpha.com
IHE: Large-Cap Pharma Cools After A Hot Summer
I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings…
1 month ago fool.com
Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
1 month ago fool.com
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
2 months ago fool.com
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
2 months ago fool.com
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.
2 months ago fool.com
IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?
The iShares U.S. Pharmaceuticals ETF (IHE) offers a higher dividend yield and significantly lower historical volatility than the State Street SPDR S&P Biotech ETF (XBI). XBI has outperformed IHE on a…
2 months ago fool.com
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
2 months ago defenseworld.net
iShares U.S. Pharmaceuticals ETF $IHE Shares Bought by Bank of America Corp DE
Bank of America Corp DE boosted its position in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 2.8% during the undefined quarter, according to the company in its most recent disclosure with the…
2 months ago barrons.com
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
3 months ago fool.com
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?
The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. Pharmaceuticals ETF (IHE). IHE concentrates exclusively on the pharmaceutical industry,…
3 months ago zacks.com
Will Generic Drug Tariffs Impact Pharma ETFs?
New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.
3 months ago invezz.com
Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide
Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge…
3 months ago benzinga.com
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
5 months ago benzinga.com
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge higher Wednesday.
9 months ago benzinga.com
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs
UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.
9 months ago benzinga.com
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
10 months ago benzinga.com
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
11 months ago benzinga.com
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
11 months ago benzinga.com
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
11 months ago benzinga.com
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
1 year ago benzinga.com
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
1 year ago benzinga.com
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
1 year ago benzinga.com
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
1 year ago benzinga.com
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
1 year ago benzinga.com
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken…
1 year ago benzinga.com
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
1 year ago benzinga.com
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
1 year ago benzinga.com
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
1 year ago benzinga.com
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
1 year ago benzinga.com
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
1 year ago benzinga.com
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
1 year ago benzinga.com
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.
1 year ago benzinga.com
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
1 year ago benzinga.com
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.
1 year ago benzinga.com
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
1 year ago benzinga.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
1 year ago benzinga.com
Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?
Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
1 year ago benzinga.com
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.
1 year ago benzinga.com
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
1 year ago benzinga.com
US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21.
1 year ago benzinga.com
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.